CD4 and metabolic dysfunction-associated steatotic liver disease: Although no NAFLD-patients were included, it is worth mentioning the study performed by Rautou et al, which identified significantly changing circulating levels of leuko-endothelial (CD31+/41-)-, pan-leukocyte (CD11a+)- and lymphocyte (CD4+)-derived EVs in patients with liver cirrhosis as compared to healthy controls.